MarketInOut Stock Screener Log In | Sign Up

Calidi Biotherapeutics Inc

NYSE • Healthcare • Biotechnology • Quote as of 10/28/2026 12:27
Calidi Biotherapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization2.43 mln
Float2.56 mln
Earnings Date11/13/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

5 / 100
Severely lagging

Debt / Equity

0.62
Moderate leverage

ROE

-426
Deeply negative

ROA

-178
Deeply negative

Business Description

Founded in 2014 and based in San Diego, California, Calidi Biotherapeutics is a clinical-stage company focused on using stem cells to deliver cancer-fighting viruses directly to tumors. Its most advanced treatment, CLD-101, is currently being tested in clinical trials for patients with high-grade brain cancer, while several other therapies targeting solid tumors and lung cancer are in earlier stages of development. The company's approach is built around proprietary platforms designed to make these viral treatments more effective and better tolerated by patients.

Key Fundamentals

EPS-36.47
ROE-426
ROIC-344
ROA-178
Interest Cover-114
EBITDA, mln-15.62
EV / EBITDA0.09
EV / EBIT0.08

Quote Details

Last 0.6883
Change 0.0283 (4.29%)
Open 0.6996
Volume 19,180
Turnover 13,202
Average Volume 45,408

Financial Ratios

Leverage Ratio2.30
Current Ratio1.68
Price / Book0.72
Price / Tangible Book0.72
Debt / Equity0.62

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio1.12
Short % of Float6.38

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -10.38% 8 / 100   
1 Month -36.27% 8 / 100   
2 Months -59.27% 6 / 100   
6 Months -80.77% 4 / 100   
1 Year -97.21% 3 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog